Evolving therapeutic landscape of primary biliary cholangitis: A review
Authors:
- Natalie E MitchellNMNatalie E Mitchell
- Shu-Yen ChanSCShu-Yen Chan
- David Jerez DiazDDDavid Jerez Diaz
- Nida AnsariNANida Ansari
- Junseo LeeJLJunseo Lee
- Patrick TwohigPTPatrick Twohig
Open Access
- 27 July 2025
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 17 (7)
Abstract
Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease characterized by progressive bile duct destruction, leading to fibrosis, cirrhosis, and eventual liver failure. Over the past two decades, significant advancements have paved the way for novel therapeutic strategies. Ursodeoxycholic acid (UDCA) has been the cornerstone of PBC management, improving survival and delaying disease progression in most patients. However, up to 40% of patients demonstrate an inadequate response to UDCA, necessitating additional treatment options. Obeticholic acid (OCA), a farnesoid X receptor agonist, has emerged as a second-line therapy, showing efficacy in reducing alkaline phosphatase levels and improving liver biochemistry. Beyond UDCA and OCA, a new wave of therapeutic agents are reshaping the PBC landscape. These include fibrates, peroxisome proliferator-activated receptor agonists and novel immunomodulatory drugs aimed at reducing autoimmune-mediated liver injury. Bile acid transport inhibitors, anti-fibrotic agents, and gut microbiome-targeted therapies are also under investigation, offering hope for personalized treatment approaches. This review highlights the evolution of PBC therapy, emphasizing the unmet needs of patients with refractory disease and the potential of emerging therapies to improve outcomes. As the therapeutic landscape continues to expand, optimizing treatment strategies through precision medicine holds the promise of transforming the management of PBC.Keywords
This publication has 58 references indexed in Scilit:
- Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up StudyGastroenterology, 2014
- Primary biliary cirrhosis and bile acidsClinics and Research in Hepatology and Gastroenterology, 2012
- Recurrent Primary Biliary Cirrhosis After Liver TransplantationAmerican Journal of Transplantation, 2010
- Bile acid transportersJournal of Lipid Research, 2009
- Primary biliary cirrhosis after liver transplantation: Influence of immunosuppression and human leukocyte antigen locus disparityLiver Transplantation, 2009
- Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic AcidGastroenterology, 2009
- Safety Considerations with Fibrate TherapyThe American Journal of Cardiology, 2007
- 6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic ActivityJournal of Medicinal Chemistry, 2002
- Ursodeoxycholic acid in the treatment of primary biliary cirrhosisGastroenterology, 1994
- A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary CirrhosisNew England Journal of Medicine, 1991